GENFIT-ADR(NASDAQ:GNFT) stock Fundamental Analysis

Fundamental Rating

Overall GNFT gets a fundamental rating of 5 out of 10. We evaluated GNFT against 571 industry peers in the Biotechnology industry. GNFT has a medium profitability rating, but doesn't score so well on its financial health evaluation. GNFT is not priced too expensively while it is growing strongly. Keep and eye on this one!

Quickly go to:

1. Profitability

1.1 Basic Checks

GNFT had positive earnings in the past year.

In the past year GNFT has reported a negative cash flow from operations.

GNFT had negative earnings in 4 of the past 5 years.

GNFT had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

GNFT's Return On Assets of 11.43% is amongst the best of the industry. GNFT outperforms 96.98% of its industry peers.

GNFT has a Return On Equity of 22.87%. This is amongst the best in the industry. GNFT outperforms 97.69% of its industry peers.

GNFT's Return On Invested Capital of 11.90% is amongst the best of the industry. GNFT outperforms 96.27% of its industry peers.

		Industry Rank	Sector Rank
ROA	11.43%
ROE	22.87%
ROIC	11.9%

ROA(3y)-1.25%

ROA(5y)-15.15%

ROE(3y)-3.71%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin of GNFT (26.51%) is better than 97.87% of its industry peers.

GNFT's Operating Margin of 28.39% is amongst the best of the industry. GNFT outperforms 97.87% of its industry peers.

Looking at the Gross Margin, with a value of 97.41%, GNFT belongs to the top of the industry, outperforming 97.16% of the companies in the same industry.

GNFT's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	28.39%
PM (TTM)	26.51%
GM	97.41%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y8.81%

GM growth 5Y4.62%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so GNFT is still creating some value.

The number of shares outstanding for GNFT remains at a similar level compared to 1 year ago.

The number of shares outstanding for GNFT has been increased compared to 5 years ago.

GNFT has a worse debt/assets ratio than last year.

2.2 Solvency

GNFT has an Altman-Z score of -0.01. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.

GNFT has a Altman-Z score of -0.01. This is in the better half of the industry: GNFT outperforms 63.41% of its industry peers.

GNFT has a Debt/Equity ratio of 0.61. This is a neutral value indicating GNFT is somewhat dependend on debt financing.

GNFT has a worse Debt to Equity ratio (0.61) than 76.73% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.61
Debt/FCF	N/A
Altman-Z	-0.01

ROIC/WACC1.59

WACC7.49%

2.3 Liquidity

GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 3.74, GNFT perfoms like the industry average, outperforming 43.87% of the companies in the same industry.

A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.

GNFT has a Quick ratio (3.74) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.74
Quick Ratio	3.74

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GNFT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 153.62%, which is quite impressive.

Looking at the last year, GNFT shows a very strong growth in Revenue. The Revenue has grown by 182.34%.

Measured over the past years, GNFT shows a very strong growth in Revenue. The Revenue has been growing by 38.49% on average per year.

EPS 1Y (TTM)153.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%226.19%

Revenue 1Y (TTM)182.34%

Revenue growth 3Y70.09%

Revenue growth 5Y38.49%

Sales Q2Q%413.61%

3.2 Future

The Earnings Per Share is expected to grow by 32.59% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 28.53% on average over the next years. This is a very strong growth

EPS Next Y389.04%

EPS Next 2Y-67.21%

EPS Next 3Y32.59%

EPS Next 5YN/A

Revenue Next Year48.34%

Revenue Next 2Y-18.76%

Revenue Next 3Y-1.28%

Revenue Next 5Y28.53%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 8.15, the valuation of GNFT can be described as reasonable.

Based on the Price/Earnings ratio, GNFT is valued cheaply inside the industry as 98.05% of the companies are valued more expensively.

Compared to an average S&P500 Price/Earnings ratio of 29.62, GNFT is valued rather cheaply.

GNFT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	8.15
Fwd PE	N/A

4.2 Price Multiples

98.93% of the companies in the same industry are more expensive than GNFT, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	7.39

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

The decent profitability rating of GNFT may justify a higher PE ratio.

GNFT's earnings are expected to grow with 32.59% in the coming years. This may justify a more expensive valuation.

PEG (NY)0.02

PEG (5Y)N/A

EPS Next 2Y-67.21%

EPS Next 3Y32.59%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GNFT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENFIT-ADR

NASDAQ:GNFT (2/21/2025, 8:24:09 PM)

3.83

-0.09 (-2.3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-07 2024-11-07

Earnings (Next)05-22 2025-05-22

Inst Owners0.9%

Inst Owner Change-99.13%

Ins Owners0.19%

Ins Owner ChangeN/A

Market Cap190.97M

Analysts90.77

Price Target10.22 (166.84%)

Short Float %0.23%

Short Ratio12.39

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-2.58%

PT rev (3m)-8.61%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)3.38%

EPS NY rev (3m)3.38%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-4.01%

Valuation

		Industry Rank	Sector Rank
PE	8.15
Fwd PE	N/A
P/S	2.17
P/FCF	N/A
P/OCF	N/A
P/B	1.87
P/tB	3.62
EV/EBITDA	7.39

EPS(TTM)0.47

EY12.27%

EPS(NY)-0.57

Fwd EYN/A

FCF(TTM)-0.9

FCFYN/A

OCF(TTM)-0.87

OCFYN/A

SpS1.76

BVpS2.04

TBVpS1.06

PEG (NY)0.02

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	11.43%
ROE	22.87%
ROCE	15.06%
ROIC	11.9%
ROICexc	19.48%
ROICexgc	37.87%
OM	28.39%
PM (TTM)	26.51%
GM	97.41%
FCFM	N/A

ROA(3y)-1.25%

ROA(5y)-15.15%

ROE(3y)-3.71%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y8.81%

GM growth 5Y4.62%

F-Score6

Asset Turnover0.43

Health

		Industry Rank	Sector Rank
Debt/Equity	0.61
Debt/FCF	N/A
Debt/EBITDA	2.34
Cap/Depr	73.22%
Cap/Sales	1.46%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.74
Quick Ratio	3.74
Altman-Z	-0.01

F-Score6

WACC7.49%

ROIC/WACC1.59

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)153.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%226.19%

EPS Next Y389.04%

EPS Next 2Y-67.21%

EPS Next 3Y32.59%

EPS Next 5YN/A

Revenue 1Y (TTM)182.34%

Revenue growth 3Y70.09%

Revenue growth 5Y38.49%

Sales Q2Q%413.61%

Revenue Next Year48.34%

Revenue Next 2Y-18.76%

Revenue Next 3Y-1.28%

Revenue Next 5Y28.53%

EBIT growth 1Y173.81%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year201.04%

EBIT Next 3Y-8.48%

EBIT Next 5YN/A

FCF growth 1Y-153.65%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-151.78%

OCF growth 3YN/A

OCF growth 5YN/A

GENFIT-ADR (GNFT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens